Shares of Lexicon Pharmaceuticals, Inc. (LXRX) rose 13 cents or 9.35%, after the company announced Friday that its irritable bowel syndrome drug showed positive results in a Phase-2 clinical trial.

The study demonstrated that patients taking one gram of the drug LX1031 four times a day experienced less pain and discomfort related to IBS over the four weeks of evaluation than did patients receiving a placebo, according to a release from the company.

The study evaluated 155 patients at 250 milligram and 1,000 milligram dosage levels, with no significant differences in side-effects to from the placebo, the company said. A presentation of the study’s results will be held in London on November 25.

Shares of Lexicon closed at $1.52 per share on Friday and were up an additional two cents in after-hours trading.